Milton M. Morris, Ph.D., NACD.DC

Independent Director | (NASDAQ: EMBC, NDSN; NYSE: MYO)

Houston, Texas, United States

About

Dr. Morris is a former CEO and tech-savvy Independent Director for both public and private companies. Dr. Morris has over 30 years of operating experience within Fortune 500, Mid-, Small- and Micro-Cap companies and is nationally recognized (AIMBE) for his leadership in successful commercialization of high-tech medical devices. Dr. Morris has a passion for, and a successful track record of leading turnarounds, building high performing teams, and leveraging positive product differentiation in highly regulated global markets to grow value.

Experience

  • Independent Director at Nordson Corporation
    Sep 2022 - Present · 3 yrs 10 mos

    Audit Committee Governance & Sustainability Committee

  • Independent Director at embecta
    Apr 2022 - Present · 4 yrs 3 mos

    Compensation Committee Technology, Quality & Regulatory Committee

  • Independent Director at Myomo, Inc.
    Jun 2021 - Present · 5 yrs 1 mo

    Compensation Committee Chair, Technology Committee

  • Founder & Principal at MEHL BioMedical, LLC
    Jan 2015 - Present · 11 yrs 6 mos

    At MEHL BioMedical, LLC our mission is to help companies extend and improve the lives of patients struggling with debilitating health conditions.

  • President & CEO at NeuSpera Medical Inc.
    Aug 2015 - Jun 2022 · 6 yrs 11 mos

    As its former Chairman and CEO, Dr. Morris led the restart of Neuspera Medical Corporation (legacy Vivonda) — successfully raising $120m of capital across 4 financings and growing its value over 400x. During his 7 year tenure, Neuspera achieved FDA approval to commercialize its novel ultraminiaturized neuromodulation system for use in Peripheral Pain and an FDA approval to complete its pivotal trial for Urge Urinary Incontinence -- a second large market vertical effecting ~7% of the adult population.